SQZ Biotechnologies

SQZ

ATLANTA, GA – – (ACCESSWIRE – December 5, 2022) – – Holzer & Holzer, LLC is investigating whether SQZ Biotechnologies Company (“SQZ Bio” or the “Company”) (NYSE: SQZ) complied with federal securities laws. On December 1, 2022, SQZ Biotechnologies announced that its Chief Executive Officer, Armon Sharei, was stepping down, effective immediately. The Company further announced that its “Board of Directors approved a restructuring plan which includes a workforce reduction of approximately 60 percent.” Following this announcement, the Company’s stock price dropped.

If you purchased SQZ Biotechnologies stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/sqz-biotechnologies/ to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

View Representation Agreement

Submit Your Information

Name(Required)

First Last

Email(Required)

Phone(Required)

Address

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Shares Purchased(Required)

Number of Shares Acquired

Acquisition Price Per Share

Shares Sold

Number of Shares Sold

Selling Price Per Share

By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.

I agree

Signed pursuant to the Uniform Electronic Transactions act as adopted by the various states and territories of the United States.

CAPTCHA